<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-EE6N0WOW</identifier><date>2016</date><creator>Detiček, Andreja</creator><creator>Janežič, Ana</creator><creator>Janžič, Andrej</creator><creator>Kos, Mitja</creator><creator>Locatelli, Igor</creator><creator>Marđetko, Nika</creator><relation>documents/doc/E/URN_NBN_SI_doc-EE6N0WOW_001.pdf</relation><relation>documents/doc/E/URN_NBN_SI_doc-EE6N0WOW_001.txt</relation><format format_type="issue">2/3</format><format format_type="volume">67</format><format format_type="type">article</format><format format_type="extent">str. 151-158</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">4081521</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-EE6N0WOW</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">alirokumab</subject><subject language_type_id="slv">družinska hiperholesterolemija</subject><subject language_type_id="slv">evolokumab</subject><subject language_type_id="slv">PCSK9</subject><subject language_type_id="slv">statinska intoleranca</subject><title>opportunities and challenges</title><title>Priložnosti in izzivi vezani na novo skupino zdravil (zaviralci PCSK9) za zniževanje holesterola LDL</title><title>The PSCK9 inhibitors - a novel therapeutic target for hypercholesterolemia</title></Record>